Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of JNJ-38431055, a Novel GPR119 Receptor Agonist and Potential Antidiabetes Agent, in Healthy Male Subjects

(2011) L B Katz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell

(2009) L. M. Lauffer et al.   DIABETES

GPR119 agonists for the treatment of type 2 diabetes

(2009) Robert M Jones et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

(2009) Bo Ahrén   NATURE REVIEWS DRUG DISCOVERY

Receptors for acylethanolamides—GPR55 and GPR119

(2009) Grzegorz Godlewski et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

A Gut Feeling for Obesity: 7TM Sensors on Enteroendocrine Cells

(2008) Maja S. Engelstoft et al.   Cell Metabolism

GLP-1: physiological effects and potential therapeutic applications

(2008) Kasper Aaboe et al.   DIABETES OBESITY & METABOLISM

A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release

(2008) Zhi-Liang Chu et al.   ENDOCRINOLOGY

Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119

(2008) Graeme Semple et al.   JOURNAL OF MEDICINAL CHEMISTRY

Gut Hormones: A Weight Off Your Mind

(2008) J. V. Gardiner et al.   JOURNAL OF NEUROENDOCRINOLOGY

GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity

(2007) H A Overton et al.   BRITISH JOURNAL OF PHARMACOLOGY